The Role of BCS (biopharmaceutics Classification System) and BDDCS (biopharmaceutics Drug Disposition Classification System) in Drug Development

Overview

Journal J Pharm Sci

Publisher Elsevier

Specialties Pharmacology
Pharmacy

Date 2012 Nov 14

PMID 23147500

Citations 68

Authors

Leslie Z Benet

Affiliations

Soon will be listed here.

Abstract

Biopharmaceutics Classification System and Biopharmaceutics Drug Distribution Classification System are complimentary, not competing, classification systems that aim to improve, simplify, and speed drug development. Although both systems are based on classifying drugs and new molecular entities into four categories using the same solubility criteria, they differ in the criterion for permeability and have different purposes. Here, the details and applications of both systems are reviewed with particular emphasis of their role in drug development.

Citing Articles

Additive manufacturing of water-soluble 3D micro molds for complex-shaped lipid microparticles.

Park J, Brugger J, Bertsch A Nat Commun. 2025; 16(1):1734.

PMID: 39966426 PMC: 11836409. DOI: 10.1038/s41467-025-56984-7.

Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.

Wu K, Kwon S, Zhou X, Fuller C, Wang X, Vadgama J Int J Mol Sci. 2024; 25(23.

PMID: 39684832 PMC: 11642056. DOI: 10.3390/ijms252313121.

Gelation during Ring-Opening Reactions of Cellulosics with Cyclic Anhydrides: Phenomena and Mechanisms.

Petrova S, Zheng Z, Heinze D, Vaissier Welborn V, Bortner M, Schmidt-Rohr K Biomacromolecules. 2024; 25(12):7777-7787.

PMID: 39571134 PMC: 11632662. DOI: 10.1021/acs.biomac.4c01081.

No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects.

Zhao L, Sun Y, Yang X, Tian L, Li L, Wang F Front Pharmacol. 2024; 15:1433663.

PMID: 39188943 PMC: 11346245. DOI: 10.3389/fphar.2024.1433663.

Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review.

Preeti , Sambhakar S, Saharan R, Narwal S, Malik R, Gahlot V Saudi Pharm J. 2023; 31(12):101870.

PMID: 38053738 PMC: 10694332. DOI: 10.1016/j.jsps.2023.101870.

References

Lau Y, Okochi H, Huang Y, Benet L . Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther. 2005; 316(2):762-71. DOI: 10.1124/jpet.105.093088. View

Lau Y, Huang Y, Frassetto L, Benet L . effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2006; 81(2):194-204. DOI: 10.1038/sj.clpt.6100038. View

Varma M, Gardner I, Steyn S, Nkansah P, Rotter C, Whitney-Pickett C . pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Mol Pharm. 2012; 9(5):1199-212. DOI: 10.1021/mp2004912. View

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

Chen M, Amidon G, Benet L, Lennernas H, Yu L . The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011; 28(7):1774-8. DOI: 10.1007/s11095-011-0438-1. View

Reyes M, Benet L . Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci. 2011; 100(9):3831-42. PMC: 3581075. DOI: 10.1002/jps.22640. View

Yang Y, Faustino P, Volpe D, Ellison C, Lyon R, Yu L . Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol Pharm. 2007; 4(4):608-14. DOI: 10.1021/mp070028i. View

Wager T, Chandrasekaran R, Hou X, Troutman M, Verhoest P, Villalobos A . Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci. 2012; 1(6):420-34. PMC: 3368653. DOI: 10.1021/cn100007x. View

Lau Y, Okochi H, Huang Y, Benet L . Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006; 34(7):1175-81. DOI: 10.1124/dmd.105.009076. View

10.

Sun H, Frassetto L, Benet L . Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2005; 109(1-2):1-11. DOI: 10.1016/j.pharmthera.2005.05.010. View

11.

He Y, Zhang W, Chen Y, Guo D, Tu J, Xu L . Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009; 405(1-2):49-52. DOI: 10.1016/j.cca.2009.04.003. View

12.

Pajouhesh H, Lenz G . Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2006; 2(4):541-53. PMC: 1201314. DOI: 10.1602/neurorx.2.4.541. View

13.

Sun H, Huang Y, Frassetto L, Benet L . Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004; 32(11):1239-46. DOI: 10.1124/dmd.104.000521. View

14.

Frymoyer A, Shugarts S, Browne M, Wu A, Frassetto L, Benet L . Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010; 88(4):540-7. PMC: 3091944. DOI: 10.1038/clpt.2010.142. View

15.

Norinder U, Haeberlein M . Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 2002; 54(3):291-313. DOI: 10.1016/s0169-409x(02)00005-4. View

16.

Broccatelli F, Larregieu C, Cruciani G, Oprea T, Benet L . Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012; 64(1):95-109. PMC: 3496430. DOI: 10.1016/j.addr.2011.12.008. View

17.

Wu C, Benet L . Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos. 2003; 31(11):1292-5. DOI: 10.1124/dmd.31.11.1292. View

18.

Chen M, Yu L . The use of drug metabolism for prediction of intestinal permeability (dagger). Mol Pharm. 2009; 6(1):74-81. DOI: 10.1021/mp8001864. View

19.

Broccatelli F, Cruciani G, Benet L, Oprea T . BDDCS class prediction for new molecular entities. Mol Pharm. 2012; 9(3):570-80. PMC: 3295927. DOI: 10.1021/mp2004302. View

20.

Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B . The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106(7):2329-33. DOI: 10.1182/blood-2005-03-1108. View